TABLE 3.
Impact of baseline variants on treatment outcome in GIFT-I
| Target and variant | SVR24 rate (%; n/N)a for: |
|||||||
|---|---|---|---|---|---|---|---|---|
| Noncirrhotic patients |
Cirrhotic patients |
|||||||
| Detection threshold by deep sequencing |
Variant detected by population sequencing | Detection threshold by deep sequencing |
Variant detected by population sequencing | |||||
| 1 to 15% | >15% | <1% (wild-type) | 1 to 15% | >15% | <1% (wild-type) | |||
| NS3 | ||||||||
| T54S | 100 (12/12) | 97 (294/303) | 100 (13/13) | 100 (1/1) | 92 (36/39) | 100 (1/1) | ||
| V55I | 100 (1/1) | 97 (305/314) | 100 (1/1) | |||||
| Y56F | 100 (3/3) | 97 (115/118) | 97 (188/194) | 97 (113/116) | 100 (3/3) | 92 (11/12) | 92 (23/25) | 91 (10/11) |
| Q80 H/K/L/M/N/R | 89 (8/9) | 95 (38/40) | 98 (260/266) | 95 (37/39) | 100 (4/4) | 100 (5/5) | 90 (28/31) | 100 (4/4) |
| S122 A/C/G/N/T/V | 98 (40/41) | 98 (114/116) | 96 (152/158) | 97 (112/116) | 100 (6/6) | 84 (16/19) | 100 (15/15) | 83 (15/18) |
| D168E | 100 (4/4) | 100 (3/3) | 97 (299/308) | 100 (3/3) | 100 (1/1) | 92 (36/39) | 100 (1/1) | |
| NS5A | ||||||||
| L28I/M/V/R | 100 (4/4) | 97 (30/31) | 97 (268/276) | 97 (30/31) | 100 (4/4) | 92 (33/36) | 100 (4/4) | |
| R30K/L/Q/R | 100 (7/7) | 98 (42/43) | 97 (253/261) | 98 (43/44) | 100 (1/1) | 100 (4/4) | 91 (32/35) | 100 (4/4) |
| L31I/F/M/V | 100 (5/5) | 100 (7/7) | 97 (290/299) | 100 (5/5) | 50 (1/2) | 95 (36/38) | 50 (1/2) | |
| Q54A/C/E/H/N/L/S/T/V/Y | 94 (30/32) | 98 (124/127) | 97 (148/152) | 98 (125/128) | 100 (4/4) | 95 (20/21) | 87 (13/15) | 95 (20/21) |
| P58A/L/Q/S/T/R | 85 (11/13) | 100 (22/22) | 97 (269/276) | 100 (23/23) | 100 (2/2) | 100 (2/2) | 99 (33/36) | 100 (2/2) |
| Q62A/C/D/E/H/K/M/N/P/L/S/R | 92 (11/12) | 100 (32/32) | 97 (259/267) | 97 (32/33) | 100 (2/2) | 92 (35/38) | 100 (2/2) | |
| A92E/S/T/V | 100 (14/14) | 94 (17/18) | 97 (271/279) | 95 (20/21) | 67 (2/3) | 100 (4/4) | 94 (31/33) | 80 (4/5) |
| Y93F | 100 (1/1) | |||||||
| Y93S | 100 (1/1) | 100 (1/1) | ||||||
a
Patients not achieving SVR due to nonvirologic reasons, e.g., early discontinuations, missing SVR time point, etc., are excluded from the analysis. Only patients with available sequences (N) are included in the analysis. Therefore, N is less than the number of patients enrolled in the study and differs by target.